AbbVie Inc. (NYSE: ABBV) stock is up nearly 2% in midday trading after delivering a beat-and-raise in its second-quarter 2025 earnings report. The biopharmaceutical giant reported global net revenue of $15.42 billion, beating expectations for $14.93 billion. The bottom line was also a beat with the company reporting earnings per share (EPS) of $2.97, which was 2% higher than the $2.91 forecast.
Investing in biotechnology stocks is often a choice between stagnant large-cap stocks and speculative small- and micro-cap companies. AbbVie stands out in that it’s truly one of the blue-chip names in the sector and the broader market.
